Press Releases and Statements

(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) released the following statement today following the U.S. Food and Drug Administration’s (FDA) recent announcement outlining scientific and technical steps to transition from animal testing to New Approach Methodologies (NAMs) for safety assessments of drug products:

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today released the following statement echoing concerns U.S. Reps. Bob Latta (OH-05), Dan Crenshaw (TX-02), and Mariannette Miller-Meeks (IA-01) raised to the U.S. Food and Drug Administration (FDA), urging the Agency to strike the simultaneous marketing portion of the preamble that is tied to the final rule for Nonprescription Drug Product With an Additional Condition for Nonprescription Use (ACNU):

(Washington, D.C.) – The Consumer Healthcare Products Association (CHPA) released the below statement today following a House Energy and Commerce Subcommittee on Health hearing featuring testimony from Kevin Menzel, President of Focus Consumer Healthcare, a CHPA member company, and other industry experts, to discuss the importance of reauthorizing the OTC Monograph Drug User Fee Program (OMUFA).

CHPA President and CEO Scott Melville released a statement today following the U.S. Senate confirming the nomination of Dr. Martin Makary to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA) by a recorded vote of 56-44.

(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) Vice President of State & Local Government Affairs Carlos Gutiérrez today released the below statement following West Virginia’s passing and signing legislation that will prohibit the sale of dietary supplements containing certain additives.

(JACKSON, Miss) – The Consumer Healthcare Products Association (CHPA) applauds Mississippi Representative Stacey Wilkes, Senator Hob Bryan, and Governor Tate Reeves for passing and signing legislation into law requiring all manufacturers of over-the-counter (OTC) medicines containing pseudoephedrine (PSE) to participate in supporting the costs and administration of the National Precursor Log Exchange (NPLEx) system – a real-time stop-sale technology that allows retailers to enforce PSE sales limits and assist law enforcement in preventing illegal PSE sales. This important step not only strengthens the NPLEx system overall, but it enhances its long-term viability in preventing illegal sales of medicines containing PSE in Mississippi.

(SAN ANTONIO) – The Consumer Healthcare Products Association (CHPA) today announced the election of Greg Bradley to serve as Chair of its Board of Directors during its March membership and board meeting held during the association’s annual Self-Care Leadership Summit (SLS) in San Antonio this week.

(SAN ANTONIO) – The Consumer Healthcare Products Association (CHPA) awarded its Ivan D. Combe Lifetime Achievement Award to longtime industry leader Chris DeWolf at the opening session of its annual Self-Care Leadership Summit (SLS) today in Texas. The Combe Award is the highest honor bestowed by the U.S. consumer healthcare industry, which recognizes the outstanding work and contributions of individuals whose lifetime of achievements have created a lasting impact on the industry, their community, and have directly improved self-care for consumers.

CHPA applauds the introduction of H.R. 1219, the Oral Health Products Inclusion Act, which would increase access to certain oral care items, including toothbrushes, toothpaste, mouthwash, and other everyday oral care essentials by recognizing them as “qualified medical expenses” that can be purchased with Flexible Spending Account (FSA) and Health Savings Account (HSA) funds.

“CHPA and its member companies look forward to working with Secretary Kennedy to advance policies that will enhance American consumers’ access to safe, effective, and affordable self-care options. With a growing demand for OTC medicines, dietary supplements, and OTC medical devices, it is imperative that our nation’s healthcare leaders expand access, streamline regulatory pathways, and reinforce public confidence through transparent, data-driven decisions. This can be achieved through the reauthorization of the Over-the-Counter Monograph Drug User Fee Program (OMUFA), Rx-to-OTC switch improvements, and the modernization of the more than 30-year-old Dietary Supplement Health and Education Act (DSHEA).